Denied

No. 20-1119

Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

Petition DENIED.

DISTRIBUTED for Conference of 6/17/2021.

Reply of petitioners Amarin Pharma, Inc., et al. filed. (Distributed)

Brief of respondent Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited in opposition filed.

Motion to extend the time to file a response is granted in part and the time is extended to and including May 18, 2021.

Response to motion from petitioner Amarin Pharma, Inc., et al. filed.

Motion to extend the time to file a response from April 29, 2021 to June 14, 2021, submitted to The Clerk.

Response Requested. (Due April 29, 2021)

DISTRIBUTED for Conference of 4/16/2021.

Brief amicus curiae of Aimed Alliance filed.

Brief amicus curiae of LiquidPower Specialty Products Inc. filed.

Waiver of right of respondents Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. to respond filed.

Brief amicus curiae of US Inventor Inc. filed.

Waiver of right of respondent Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited to respond filed.

Petition for a writ of certiorari filed. (Response due March 18, 2021)

Parties

Amarin Pharma, Inc., et al., Petitioner, represented by Seth P. Waxman

Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Respondent, represented by Constance S. Huttner

Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited, Respondent, represented by Charles Bennett Klein

Amici Curiae

Aimed Alliance, Amicus Curiae, represented by Ashley C. Parrish

LiquidPower Specialty Products Inc., Amicus Curiae, represented by Zachary D. Tripp

US Inventor Inc., Amicus Curiae, represented by Robert P. Greenspoon

 
Last updated: July 24, 2021